Sign Up
Stories
BioArctic's LEQEMBI Wins Awards, Eisai Expects Revenue, and New Data on Subcutaneous Formulation
Share
Alzheimer's Innovations: A Clinical Adva...
ADvantage Therapeutics Appoints Professo...
AMX0035 for PSP: Phase 3 Trial Commences
ANJESO Drug Insight and Market Forecast
Overview
API
BioArctic's LEQEMBI (LEQEMBI) wins two categories at The Scrip Awards 2023, including Best New Drug and Clinical Advance of the Year. Eisai expects Leqembi to generate revenue of $66.5 million by March 2024. Eisai and Biogen present new data on the subcutaneous formulation of LEQEMBI, showing it clears amyloid plaques more effectively than intravenous infusion. BioArctic and Eisai are preparing for a joint commercialization in the Nordics.
Ask a question
How does LEQEMBI differ from other Alzheimer's drugs on the market?
What are the potential implications of the subcutaneous formulation of LEQEMBI on patient care?
What challenges might arise in the joint commercialization of LEQEMBI in the Nordics?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Apr 2023
Jun 2023
Aug 2023
Oct 2023
Coverage